Navigation Links
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Date:8/2/2009

LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. The Company also announced that the U.S. Food and Drug Administration (FDA) has accepted its treatment protocol for velaglucerase alfa and that Shire has begun its rolling submission of the New Drug Application (NDA) for velaglucerase alfa allowed under the Fast Track process.

"We are very pleased with the progress of the velaglucerase alfa program from both a clinical and regulatory perspective," said Sylvie Gregoire, President of Shire Human Genetic Therapies. "This data are consistent with those previously reported from the Phase I/II and extension studies. We will continue to work diligently with the FDA and other regulatory agencies to make velaglucerase alfa available as soon as possible to help meet the needs of the Gaucher community."

Shire's velaglucerase alfa program is the largest and most comprehensive set of Phase III clinical trials conducted to date for Gaucher disease. Over 100 patients at 24 sites in 10 countries around the world have participated in the clinical studies.

Velaglucerase alfa is made using Shire's proprietary technology, in a human cell line. The enzyme produced has the exact human amino acid sequence and carries a human glycosylation pattern.

Phase III Study Overview and Results

The first trial in the Phase III program to be completed was a multicenter, randomized, double-blind, two dose study of velaglucerase alfa in patients with Type 1 Gaucher disease. The primary goal of this study was to evaluate the safe
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9pthtm/home_healthcare ... Healthcare Global Market - Forecast to 2020" report ... is expected to reach more than $300+ billion growing ... home healthcare equipment market is expected to grow at ... Home healthcare is gaining a tremendous attention over hospitals ...
(Date:5/5/2015)... May 5, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... of $4.0 million for the three months ended March ... loss of $22.6 million for the same period in ... higher revenue from milestone payments earned from its partners ... GAAP basis, Isis reported a loss from operations of ...
(Date:5/5/2015)... Big Market Research presents a detailed analysis ... , ( France , Germany ... UK) and Japan . Current scientific views on ... the 5-year test volume and sales forecasts by country for HAV ... Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in ...
Breaking Medicine Technology:Global Home Healthcare Global Market 2015 - Forecast to 2020 for the $300 Billion Market 2Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 132015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3
... WASHINGTON, April 5, 2011 The American Center for Law ... sweeping victory for pro-life pharmacy owners in Illinois after a ... today issued a decision striking down a state law that ... of emergency contraception, even if doing so violates their religious ...
... April 5, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... that the Company intends to release its first quarter 2011 ... open of the U.S. financial markets.  The Company will also ... Time on April 27, 2011 to discuss its financial results ...
Cached Medicine Technology:ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle 2ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle 3Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings 2
(Date:5/5/2015)... 06, 2015 Social Media Regulatory Affairs ... Media Your Most Powerful Marketing Tool and Get the ... http://www.fdanews.com/SocialMedia , Social media … Is it ... media’s reach. Patients are using it — learning about ... what they’ve discovered. , But, it can become a ...
(Date:5/5/2015)... 2015 The Journal of ... “ Priority interventions to improve the management of ... research of the ACCORD program ” , As ... actors, including clinicians, patients and family members, managers, ... which included knowledge gap, “work in silos”, lack ...
(Date:5/5/2015)... May 05, 2015 AxoGen, Inc. ... on the $1.6 billion peripheral nerve repair market, reported ... ended March 31, 2015 compared to $3.14 million in ... adoption of our proprietary portfolio of nerve repair products ... AxoGuard® Nerve Protector – and our solid sales execution ...
(Date:5/5/2015)... Doylestown, PA (PRWEB) May 05, 2015 The ... , raised $110,000 to benefit their global research, outreach and ... and silent auction, and awards ceremony that attracted hundreds of ... anniversary of the discovery of the hepatitis B virus (HBV) ... Dr. Blumberg received the Nobel Prize in Medicine for his ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Baptist Medical ... Commission on Cancer (CoC) of the American College of ... program must meet more than 30 Commission on Cancer ... a survey process, and maintain levels of excellence in ... When patients choose to seek care locally at a ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 3Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 4Health News:Priority interventions in chronic non-cancer pain published by Dove Medical Press 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4
... FRIDAY, Oct. 29 (HealthDay News) -- More than half ... ill patients want to have full control over life-support ... doctors, finds a new study. It included 230 ... mechanical ventilation who had about a 50 percent chance ...
... 28, 2010) -- Scientists at Weill Cornell Medical College have ... viruses, two lethal and emerging viruses for which there is ... lead to new therapies for measles, mumps and the flu. ... journal Public Library of Science (PLoS) Pathogens . The ...
... Strong immunity may play a key role in determining long ... fertility, a Princeton University study has concluded. An 11-year ... remote island off the coast of Scotland that gauged the ... some people get sicker than others when exposed to the ...
... have identified a mechanism controlling the function of a ... may function to prevent abnormal tumor growth. When the ... a phosphate, it no longer binds DNA, changing the ... a new diagnostic marker (phosphorylated TCF3) that may be ...
... , THURSDAY, Oct. 28 (HealthDay News) Early humans were ... ago in Africa, more than 50,000 years earlier than previously ... that modern behavior developed over time during the Middle Stone ... Europe, as some scientists have thought. Researchers from the ...
... Developing a molecular fingerprint for head and neck cancer ... and often-times disfiguring form of cancer, according to researchers at ... taken the first step toward doing that by identifying five ... genes, tumor grade, and vascular invasion and location of the ...
Cached Medicine News:Health News:Most Health Proxies Would Make End-of-Life Decisions Themselves: Study 2Health News:Potential new treatment for deadly nipah and hendra viruses identified by Weill Cornell researchers 2Health News:Wild Scottish sheep could help explain differences in immunity 2Health News:Wild Scottish sheep could help explain differences in immunity 3Health News:Newly discovered regulatory mechanism essential for embryo development and may contribute to cancer 2Health News:Early Humans More Advanced Than Thought 2Health News:Study identifies 5 risk factors for late-stage head and neck cancer 2Health News:Study identifies 5 risk factors for late-stage head and neck cancer 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: